Application of AOH1996 in preparation of medicine for treating echinococcosis
Through AOH1996, the interaction between PCNA and RNA polymerase II was enhanced, and the drugs for echinococcosis were developed, which solved the problem that surgical removal in the prior art was difficult to completely eradicate echinococcosis, and achieved the protocele of echinococcosis and Effective inhibition and killing of vesicles provide an efficient prevention and control of hydatis diseases.
Patent Information
- Application Number
- CN202411204564.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-30
AI Technical Summary
The existing treatment methods for hydococcusia mainly rely on surgical resection, which cannot effectively cure advanced lesions and has a high recurrence rate. It is difficult to completely eradicate echinococcosis by drug treatment. The existing drugs have limited selective killing effect on echinococcosis.
Using AOH1996 as a small molecule proliferating cell nuclear antigen (PCNA) inhibitor, the application of AOH1996 in the preparation of drugs for the treatment of echinococcosis, including inhibition and inhibition by enhancing the interaction between PCNA and RNA polymerase II maximum subunit RPB1. Kill the protoceleblasts and vesicles of Echinococcus, destroy their morphology, and promote their death.
AOH1996 significantly inhibits and kills the protocelebone and vesicles of Echinococcus multi-apartment, achieving dose-dependent and time-dependent killing effects, providing technical support for efficient prevention and control of hydatis disease.
Smart Images

Figure CN119074709A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of AOH1996 in preparing a medicine for treating echinococcosis. Background Art
[0002] Echinococcosis, also known as echinococcosis, is a zoonotic parasitic disease caused by the larvae of the tapeworm Echinococcus, which seriously endangers people's health and the development of animal husbandry. The disease is distributed worldwide, and its lesions are usually located in the liver, but may also develop in the lungs. The current treatment for echinococcosis mainly relies on surgical treatment, that is, surgical removal of the tumor-like hydatid cysts in the liver.
[0003] In recent years, surgical resection has provided a good prospect for the cure of echinococcosis and has effectively reduced the recurrence rate of the disease. However, surgical treatment is only suitable for early lesions, when the lesions can be completely removed without affecting the surrounding organs. However, since most patients with echinococcosis are diagnosed almost in the late stage, the cysts are large and close to important organs, making complete radical removal impossible. In addition, the head segment may be missed and left over during surgery, and drug treatment is required to prevent the recurrence of echinococcosis.
[0004] AOH1996 is an orally active small molecule proliferating cell nuclear antigen (PCNA) inhibitor, which can be obtained by adding a methoxy group to the meta position of the terminal benzene ring of AOH1160, and can enhance the interaction between PCNA and RPB1, the largest subunit of RNA polymerase II. Prior art reports that AOH1996 can selectively kill cancer cells and is often used to prepare anticancer drugs. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a new use of AOH1996, namely, the use of AOH1996 in the preparation of a drug for treating echinococcosis.
[0006] The invention provides application of AOH1996 in preparing medicine for treating echinococcosis.
[0007] Preferably, the echinococcosis includes multilocular echinococcosis.
[0008] Preferably, the drug comprises at least one of the following: inhibiting the activity of multilocular echinococcosis protoscolex and / or multilocular echinococcosis vesicles, destroying the morphology of multilocular echinococcosis protoscolex and / or multilocular echinococcosis vesicles, and promoting the death of multilocular echinococcosis protoscolex and / or multilocular echinococcosis vesicles.
[0009] Preferably, the dosage form of the drug includes an oral dosage form;
[0010] The oral dosage form includes at least one of the following: tablets, capsules and powders.
[0011] Preferably, the concentration of AOH1996 in the drug is not less than 20 μM.
[0012] Preferably, the concentration of AOH1996 in the drug is 40-80 μM.
[0013] The invention provides the use of AOH1996 in preparing a preparation for killing echinococcosis in vitro.
[0014] Preferably, the echinococcosis includes echinococcosis protoscoleces and / or echinococcosis cysts.
[0015] Preferably, the echinococcus comprises Echinococcus multilocularis.
[0016] The invention provides a method for killing echinococcosis in vitro, wherein a sample containing echinococcosis is placed in an environment containing AOH1996 for culture; the concentration of the AOH1996 is not less than 20 μM.
[0017] The present invention provides the use of AOH1996 in the preparation of a drug for treating echinococcosis. The present invention takes different life history forms of echinococcosis (echinococcosis protoscoleces and echinococcosis cysts) as research objects, and carries out the efficacy of AOH1996 on echinococcosis. The experimental results show that AOH1996 can effectively inhibit the vitality of multilocular echinococcosis protoscoleces and vesicles, and the administration of AOH1996 can destroy the original morphology of multilocular echinococcosis protoscoleces and vesicles, promote the death of multilocular echinococcosis protoscoleces, and achieve the efficacy of killing echinococcosis, and the killing effect is dose-dependent. Therefore, the application scheme provided by the present invention will provide technical support for the efficient prevention and treatment of echinococcosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The figure shows the results of protoscolecene activity determination after 96h of in vitro culture of different concentrations of AOH1996;
[0019] Figure 2 This is the result graph of the mortality of protoscoleces of Echinococcus multilocularis caused by different concentrations of AOH1996;
[0020] Figure 3 This is the result diagram of the killing effect of AOH1996 on vesicles in vitro;
[0021] Figure 4 This is a diagram showing the changes in the internal structure of the protoscolex 5 days after the action of AOH1996. DETAILED DESCRIPTION
[0022] The invention provides application of AOH1996 in preparing medicine for treating echinococcosis.
[0023] In the present invention, the molecular formula of AOH1996 is C26 H 22 N 2 O 4 , CAS: 2089314-64-5, the structural formula is shown in Formula I:
[0024]
[0025] In the present invention, the echinococcosis preferably includes multilocular echinococcosis (alveolar echinococcosis). The echinococcosis includes echinococcosis in animals or echinococcosis in humans. The echinococcosis is preferably hepatic echinococcosis according to the diseased site.
[0026] In the present invention, the dosage form of the drug preferably includes an oral dosage form. The oral dosage form preferably includes at least one of the following: tablets, capsules and powders. The oral dosage form is preferably prepared in combination with pharmaceutically acceptable excipients according to different dosage forms. The present invention has no restrictions on the preparation method of the oral dosage form, and the preparation method of the oral dosage form known in the art can be used. The concentration of AOH1996 in the drug is preferably not less than 20 μM, more preferably 40 to 80 μM. The usage of the drug is continuous administration for at least 5 days, more preferably 6 to 10 days. The dosage of the drug is preferably 40 to 80 μM.
[0027] In the present invention, the drug preferably includes at least one of the following: inhibiting the activity of multilocular echinococcosis protoscolex and / or multilocular echinococcosis vesicles, destroying the morphology of multilocular echinococcosis protoscolex and / or multilocular echinococcosis vesicles, and promoting the death of multilocular echinococcosis protoscolex and / or multilocular echinococcosis vesicles.
[0028] In one embodiment of the present invention, the effects of different concentrations of AOH1996 on the activity and mortality of Echinococcus multilocularis protoscolex were evaluated, and the PI staining results showed that compared with the blank control group and the DMSO group, the number of live protoscolex decreased significantly at a drug concentration of 20 μM, and the number of dead protoscolex increased significantly at drug concentrations of 40 μM and 80 μM.
[0029] In another embodiment of the present invention, the effects of different concentrations of AOH1996 on the morphology of the protoscolex of multilocular Echinococcus were evaluated. The results showed that the cyst walls of the protoscolex of the blank group and the DMSO group were intact, with vesicles of different sizes and shapes arranged regularly, and containing a variety of different types of cells. After the administration of AOH1996, the protoscolex shrank, the structure was loose, the morphology was incomplete, the cyst wall became thinner, and the number of cilia decreased. This shows that the administration of AOH1996 can affect the normal morphology of the protoscolex of multilocular Echinococcus, thereby leading to its normal growth.
[0030] In another embodiment of the present invention, the effects of different concentrations of AOH1996 on the morphology of Echinococcus multilocularis vesicles were evaluated. The results showed that the vesicles in the DMSO group were plump in morphology, smooth in surface, and without collapse, while the vesicles treated with AOH1996 underwent significant changes in morphology, with collapse and shrinkage, affecting the normal morphology of the vesicles.
[0031] The invention provides the use of AOH1996 in preparing a preparation for killing echinococcosis in vitro.
[0032] In the present invention, the echinococcosis preferably includes echinococcosis protoscoleces and / or echinococcosis cysts. The echinococcosis preferably includes multilocular echinococcosis. The present invention does not impose any particular limitation on the type of the preparation, and any preparation type known in the art can be used.
[0033] The invention provides a method for killing echinococcosis in vitro, wherein a sample containing echinococcosis is placed in an environment containing AOH1996 for culture; the concentration of the AOH1996 is not less than 20 μM.
[0034] In the present invention, the concentration of AOH1996 is preferably 40 to 80 μM, and most preferably 60 μM. The environment containing AOH1996 is preferably a culture medium containing AOH1996. The culture medium is preferably a DMEM culture medium without fetal bovine serum. The culture time is preferably 20 to 26 hours, and more preferably 24 hours.
[0035] In the embodiment of the present invention, AOH1996 was used to kill multilocular Echinococcus. The results showed that 20μM AOH1996 showed a significant decrease compared with the blank group and the DMSO control group. It can be seen from the activity curve that with the increase of drug concentration and the extension of medication time, the inhibition rate of protoscoleces increased. This effect is dose-dependent and time-dependent. After 7 days of action of 80μM AOH1996, the vesicle mortality rate can reach 95%.
[0036] The application of AOH1996 provided by the present invention in the preparation of a drug for treating echinococcosis is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0037] Example 1
[0038] Effect of AOH1996 on protoscoleces of Echinococcus multilocularis in vitro
[0039] After killing the gerbils infected with Echinococcus multilocularis by cervical dislocation, the surface of the gerbils was sprayed with 75% alcohol for sterilization, and then transferred to a clean bench to separate the protoscoleces under sterile conditions. The multilocular Echinococcus cysts were peeled off from the gerbil tissues, the residual tissues were removed, and placed in pre-cooled PBS buffer (containing 100U / mL penicillin and 100U / mL streptomycin), and washed repeatedly 3 times. Use ophthalmic scissors to cut the vesicle tissue into pieces, and then transfer the cut mixture to a beaker with an 80-mesh copper mesh, and slowly grind it with a pestle until all the mixture is filtered through the 80-mesh copper mesh. Add an appropriate amount of PBS buffer, let the worms settle naturally, and discard the supernatant until the solution is clear. Under a microscope, the protoscoleces were observed to have a full structure, an oval shape, a clear and complete structure, and obvious peristalsis. The protoscole was divided into DMEM medium without fetal bovine serum (penicillin 100U / mL, streptomycin 100U / mL) and placed at 37°C and 5% CO 2 Culture in an incubator.
[0040] Experimental groups: blank group, DMSO group (solvent control), 20μM AOH1996 group, 40μM AOH1996 group, 80μM AOH1996 group. Take a 48-well plate, set 1mL system in each well, and add about 1000 protoscoleces to the culture medium of each group according to the above groups, and place at 37℃, 5% CO 2 The cells were cultured in an incubator and the effects of the drugs on the morphology and vitality of the protoscolex of multilocular Echinococcus were observed under a microscope at different culture times.
[0041] Data statistical method: Starting from 24 hours after drug addition, 100 μL of culture solution (containing 90 to 120 protoscoles on average) was uniformly extracted from each well every day, stained with 1% PI dye for 15 minutes, and the dye in the solution was washed away with PBS buffer, and the vitality of the protoscoles was observed under a fluorescence microscope. The live protoscoles were not colored and active; the protoscoles that emitted strong red fluorescence and had no obvious peristalsis were considered dead protoscoles. The experiment was repeated three times. The mortality rate of the protoscoles was calculated according to formula I.
[0042] Protoscolecephalic mortality rate (%) = number of protoscolecephalic deaths / 100% Formula I
[0043] Results Figure 1 After 1% PI staining, compared with the blank control group and DMSO group, the number of dead protoscoleces at 40μM and 80μM drug concentrations increased significantly.
[0044] Mortality results are shown in Figure 2Compared with the blank group and the DMSO control group, the activity of 20μM AOH1996 decreased significantly, and it can be seen from the activity curve that with the increase of drug concentration and the extension of medication time, the inhibition rate of protoscolecus increased. This effect is dose-dependent and time-dependent. After 7 days of treatment with 80μM AOH1996, the vesicle mortality rate can reach about 95%.
[0045] Example 2
[0046] Effect of AOH1996 on Echinococcus multilocularis vesicles in vitro
[0047] The treated protoscoleces (about 2000 cells / mL) were transferred into DMEM medium containing 10% fetal bovine serum (penicillin 100 U / mL, streptomycin 100 U / mL), and 1×10 6 Rat hepatoma cells (RH35) were cultured at 37°C and 5% CO 2 Co-culture with the protoscolecere in an incubator for 1 to 2 months, change half of the medium every 3 days, and select vesicles with a diameter range of about 2 to 4 mm for the experiment.
[0048] Experimental groups: blank group, DMSO group (solvent control), 20μM AOH1996 group, 40μM AOH1996 group, 80μM AOH1996 group. The vesicles were transferred to PBS and washed three times, and then distributed into 24-well plates (20-30 vesicles per well). Each well was set up with 2 mL of system, and DMEM medium without fetal bovine serum (penicillin 100U / mL, streptomycin 100U / mL) was added, and the plates were placed at 37°C and 5% CO. 2 Data statistical method: Starting from 24 hours after drug addition, the morphological changes of vesicles were observed under an inverted microscope.
[0049] Results Figure 3 . Observation under an inverted microscope showed that the vesicles in the DMSO group were full in morphology, smooth in surface, and did not collapse. Compared with the DMSO group, after 9 days of exposure to different concentrations of AOH1996, the vesicles had significant changes in morphology, with collapse and shrinkage.
[0050] Example 3
[0051] AOH1996 affects the internal structure of the protoscole
[0052] While measuring the vitality, randomly select the corresponding protoscolex for sectioning to observe the changes in the internal structure of the protoscolex. Wash with PBS three times, precipitate naturally, and fix with 4% paraformaldehyde for 24 hours. Remove the supernatant, dehydrate with alcohol and soak in wax step by step, 75% alcohol for 4 hours, 85% alcohol for 2 hours, 90% alcohol for 2 hours, 95% alcohol for 1 hour, anhydrous ethanol I for 30 minutes, anhydrous ethanol II for 30 minutes, alcohol benzene for 5-10 minutes, xylene I for 5-10 minutes, xylene II for 5-10 minutes, paraffin I melted at 65℃ for 1 hour, paraffin II melted at 65℃ for 1 hour, and paraffin III melted at 65℃ for 1 hour. Embed the tissue soaked in wax in an embedding machine, fix it and trim it; place the trimmed wax block in a paraffin slicer and slice it with a thickness of 4μm, and observe and collect pictures under a scanning electron microscope.
[0053] Figure 4 The internal structural changes of the protoscolecus after 5 days of AOH1996 treatment. Under an electron microscope, the cyst walls of the protoscolecus in the blank group and the DMSO group were intact, with vesicles of different sizes and shapes arranged regularly and containing a variety of different types of cells. After the action of AOH1996, the protoscolecus contracted, the structure became loose, the morphology was incomplete, the cyst wall became thinner, and the number of cilia decreased.
[0054] From the results of the above examples, it can be seen that AOH1996 has a killing effect on the protoscoleces and vesicles of Echinococcus multilocularis in vitro. The research results provide technical support for the efficient prevention and treatment of echinococcosis.
[0055] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of AOH1996 in the preparation of drugs for the treatment of echinococcosis.
2. The use according to claim 1, characterized in that: The echinococcosis includes multilocular echinococcosis.
3. The application according to claim 1, characterized in that: The drug comprises at least one of the following: inhibiting the activity of multilocular echinococcosis protoscolices and / or multilocular echinococcosis vesicles, destroying the morphology of multilocular echinococcosis protoscolices and / or multilocular echinococcosis vesicles, and promoting the death of multilocular echinococcosis protoscolices and / or multilocular echinococcosis vesicles.
4. The use according to claim 1, characterized in that: The dosage form of the drug includes an oral dosage form; The oral dosage form includes at least one of the following: tablets, capsules and powders.
5. The use according to claim 1, characterized in that: The concentration of AOH1996 in the drug is not less than 20 μM.
6. The use according to claim 1, characterized in that: The concentration of AOH1996 in the drug is 40-80 μM.
7. Application of AOH1996 in the preparation of preparations for killing Echinococcus in vitro.
8. The use according to claim 7, characterized in that: The echinococcosis includes echinococcosis protoscoleces and / or echinococcosis cysts.
9. The use according to claim 7 or 8, characterized in that: The echinococcosis includes multilocular echinococcosis.
10. A method for killing echinococcosis in vitro, characterized in that: The samples containing Echinococcus were placed in an environment containing AOH1996 for cultivation; The concentration of AOH1996 is not less than 20 μM.
Citation Information
Patent Citations
Application of tacrine to preparation of medicine for treating echinococcosis
CN106176747A
Preparation method of N-(2-((2-(3-methoxyphenoxy) phenyl) amino)-2-acetoxy)-1-naphthylamine
CN117603081A
Novel compounds possessing Anti-echinococcal activity
IN201611004817A
Method for predicting echinococcosis recurrence
RU2313275C1
Cited By
Application of all-transretinoic acid in preparation of medicine for treating echinococcosis infection
CN121102190A
